Urine metabolomic analysis identifies potential biomarkers and pathogenic pathways in kidney cancer

OMICS A Journal of Integrative Biology

Volumn 15, Issue 5, 2011, Pages 293-303

  Kim, Kyoungmi ^a   Taylor, Sandra L ^a   Ganti, Sheila ^a   Guo, Lining ^c   Osier, Michael V ^d   Weiss, Robert H ^a,b,e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c METABOLON INC   (United States)

^d ROCHESTER INSTITUTE OF TECHNOLOGY   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 OXOGLUTARIC ACID; 4 HYDROXYBENZOIC ACID; 4 HYDROXYPHENYLACETIC ACID; BETAINE; BIOLOGICAL MARKER; BUTYRIC ACID DERIVATIVE; FRUCTOSE; GALACTITOL; GENTISIC ACID; GLUCOSE DERIVATIVE; GLYCINE DERIVATIVE; QUINOLINIC ACID; THYMOL;

ARTICLE; CANCER CELL CULTURE; CARCINOGENESIS; CONTROLLED STUDY; HUMAN; KIDNEY CANCER; METABOLITE; METABOLOMICS; PRIORITY JOURNAL; URINE LEVEL;

CARCINOMA, RENAL CELL; CELL LINE, TUMOR; HUMANS; KIDNEY NEOPLASMS; METABOLIC NETWORKS AND PATHWAYS; METABOLOMICS; REPRODUCIBILITY OF RESULTS; TUMOR MARKERS, BIOLOGICAL;

EID: 79956159637     PISSN: 15362310     EISSN: 15362310     Source Type: Journal    
DOI: 10.1089/omi.2010.0094     Document Type: Article

References (22)

1. Ashidate, K., Kawamura, M., Mimura, D., Tohda, H., Miyazaki, S., Teramoto, T., et al. (2005). Gentisic acid, an aspirin metabolite, inhibits oxidation of low-density lipoprotein and the formation of cholesterol ester hydroperoxides in human plasma. Eur J Pharmacol 513, 173-179. (Pubitemid 40616061)
2. Benjamini, Y., and Hochberg, Y. (1995). Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc B 57, 289-300.
3. Evans, A.M., Dehaven, C.D., Barrett, T., Mitchell, M., and Milgram, E. (2009). Integrated, nontargeted ultrahigh performance liquid chromatography/electrospray ionization tandem mass spectrometry platform for the identification and relative quantification of the small-molecule complement of biological systems. Anal Chem 81, 6656-6667.
4. Grootveld, M., and Halliwell, B. (1986). Aromatic hydroxylation as a potential measure of hydroxyl-radical formation in vivo. Identification of hydroxylated derivatives of salicylate in human body fluids. Biochem J 237, 499-504. (Pubitemid 16043709)
5. Jentzmik, F., Stephan, C., Miller, K., Schrader, M., Erbersdobler, A., Kristiansen, G., et al. (2010). Sarcosine in urine after digital rectal examination fails as a marker in prostate cancer detection and identification of aggressive tumours. Eur Urol.
6. Kim, J.W., and Dang, C.V. (2006). Cancer's molecular sweet tooth and the Warburg effect. Cancer Res 66, 8927-8930. (Pubitemid 44521105)
7. Kim, K., Aronov, P., Zakharkin, S.O., Anderson, D., Perroud, B., Thompson, I.M., et al. (2009). Urine metabolomics analysis for kidney cancer detection and biomarker discovery. Mol Cell Proteomics 8, 558-570.
8. Kind, T., Tolstikov, V., Fiehn, O., and Weiss, R.H. (2007). A comprehensive urinary metabolomic approach for identifying kidney cancer. Anal Biochem Klahr, S., and Schoolwerth, A.C. (1972). Renal gluconeogenesis: effects of quinolinic acid. Biochim Biophys Acta 279, 157-162.
9. Pavlidis, P., Qin, J., Arango, V., Mann, J.J., and Sibille, E. (2004). Using the gene ontology for microarray data mining: a comparison of methods and application to age effects in human prefrontal cortex. Neurochem Res 29, 1213-1222. (Pubitemid 39023495)
10. Perroud, B., Ishimaru, T., Borowsky, A.D., and Weiss, R.H. (2009). Grade-dependent proteomic characterization of kidney cancer. Mol.Cell Proteomics 8, 971-985.
11. Saude, E.J., and Sykes, B.D. (2007). Urine stability for metabolomic studies: effects of preparation and storage. Metabolomics 3, 19-27. (Pubitemid 46453528)
12. Saude, E.J., Adamko, D., Rowe, B.H., Marrie, T., and Sykes, B.D. (2007). Variation of metabolites in normal human urine. Metabolomics 3, 439-451. (Pubitemid 350090674)
13. Schwarcz, R. (2004). The kynurenine pathway of tryptophan degradation as a drug target. Curr Opin Pharmacol 4, 12-17. (Pubitemid 38145832)
14. Sreekumar, A., Poisson, L.M., Rajendiran, T.M., Khan, A.P., Cao, Q., Yu, J., et al. (2009). Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature 457, 910-914.
15. Stone, T.W., Forrest, C.M., Mackay, G.M., Stoy, N., and Darlington, L.G. (2007). Tryptophan, adenosine, neurodegeneration and neuroprotection. Metab Brain Dis 22, 337-352.
16. Struys, E.A., Heijboer, A.C., Van, M.J., Jakobs, C., and Blankenstein, M.A. (2010). Serum sarcosine is not a marker for prostate cancer. Ann Clin Biochem 47, 282.
17. Unwin, R.D., Craven, R.A., Harnden, P., Hanrahan, S., Totty, N., Knowles, M., et al. (2003). Proteomic changes in renal cancer and co-ordinate demonstration of both the glycolytic and mitochondrial aspects of the Warburg effect. Proteomics 3, 1620-1632. (Pubitemid 37048086)
18. Wagner, B.M., Donnarumma, F., Wintersteiger, R., Windischhofer, W., & Leis, H.J. (2010). Simultaneous quantitative determination of alpha-ketoglutaric acid and 5-hydroxymethylfurfural in human plasma by gas chromatography-mass spectrometry. Anal Bioanal Chem 396, 2629-2637.
19. Warburg, O. (1956). On the origin of cancer cells. Science 123, 309-314.
20. Weiss, R.H., and Lin, P.-Y. (2006). Kidney cancer: identification of novel targets for therapy. Kidney Int 69, 224-232. (Pubitemid 43323071)
21. Yoshimura, H., Sakai, T., Kuwahara, Y., Ito, M., Tsuritani, K., Hirasawa,Y., et al. (2009). Effects of kynurenine metabolites on mesangial cell proliferation and gene expression. Exp Mol Pathol 87, 70-75.
22. Zheng, X., Jiang, F., Katakowski, M., Zhang, Z.G., Lu, Q.E., and Chopp, M. (2009). ADAM17 promotes breast cancer cell malignant phenotype through EGFR-PI3K-AKT activation. Cancer Biol Ther 8, 1045-1054.